Undisclosed musculoskeletal-related mRNA target

The 'Undisclosed musculoskeletal-related mRNA target' refers to a proprietary messenger RNA (mRNA) sequence currently under development as a therapeutic for musculoskeletal and neuromuscular conditions. mRNA therapeutics in this therapeutic area typically function by instructing host cells to produce specific proteins that can promote muscle growth, inhibit muscle degradation, or replace missing structural proteins. For example, candidates in this category may encode for Follistatin (FST) to induce hypertrophy, or express antibodies that neutralize Myostatin (GDF8) to prevent muscle wasting. Major biotechnology companies, including Moderna and BioNTech, have historically listed undisclosed musculoskeletal programs in their pipelines, often utilizing lipid nanoparticle (LNP) delivery systems to target skeletal muscle. These therapies aim to address significant unmet medical needs in diseases such as sarcopenia, Duchenne muscular dystrophy (DMD), and other rare neuromuscular disorders.

Other names

Undisclosed musculoskeletal mRNAUndisclosed muscle-related mRNAProprietary musculoskeletal mRNA candidate

Protein replacement or endogenous expression of therapeutic proteins/antibodies via mRNA translation in target tissues.